Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan Triple Therapy in H. pylori
NCT05933031Phase 2Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tegoprazan in Helicobacter pylori infection (3 arms), sponsored by HK inno.N Corporation. Primary endpoint: H. pylori eradication rate at 42 days. Status: unknown.
02
Drugs
tegoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05933031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933031.